Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 685 / https://doi.org/10.3332/ecancer.2016.685

Special Issue

Health technology assessment and value: the cancer value label (CAVALA) methodology

In modern health care systems, the soaring prices of drugs pose at least three major challenges: the growing economic burden of diseases, the uncertainty regarding innovation in health care, and the use of generic drugs and new indications.

In this context, the assessment of health care technology is not just about drugs, it is about ensuring that the system’s resources, namely financial, yield maximum health benefits. So, the assessment is about relating inputs with outputs; and also, resources with health-related outcomes. However, this method is based on specific assumptions and has its shortcomings.

This paper proposes a methodology called Cancer Value Label (CAVALA) which is a holistic and flexible concept of value. CAVALA overcomes the rationale that suffers from the communicational trap of having to discuss money versus life years gained. Some examples of CAVALA demonstrate that it has the potential to support health care decisions. 

Using a step-by-step approach, we show how CAVALA can be implemented and further extended. We discuss its main uses to assess outcome selections, the pricing of drugs, and the decisions on the reimbursement of new drugs and indications.

Keywords: cancer, health technology assessment, economic evaluation, quality-adjusted life years, health care costs, outcomes measures

Loading Article Metrics ... Please wait

Related articles

Research: Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Abstract | Full Article | PDF Published: 10 Jul 2019 / https://doi.org/10.3332/ecancer.2019.937

Review: Challenges and shifting paradigms in clinical trials in oncology, the case for immunological and targeted therapies

Abstract | Full Article | PDF Published: 05 Jul 2019 / https://doi.org/10.3332/ecancer.2019.936

Research: Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

Abstract | Full Article | PDF Published: 27 Jun 2019 / https://doi.org/10.3332/ecancer.2019.935

Research: Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy

Abstract | Full Article | PDF Published: 06 Jun 2019 / https://doi.org/10.3332/ecancer.2019.934

Case Report: Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis

Abstract | Full Article | PDF Published: 03 Jun 2019 / https://doi.org/10.3332/ecancer.2019.933



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation